Valuation: Nipro Corporation

Market Cap 217B 1.38B 1.22B 1.14B 1.04B 1.96B 132B 1.98B 13.82B 5.36B 67.69B 5.17B 5.06B P/E 2027 *
13.5x
P/E 2028 * 10.2x
Enterprise Value 718B 4.55B 4.05B 3.78B 3.44B 6.49B 438B 6.55B 45.69B 17.71B 224B 17.1B 16.72B EV / Sales 2027 *
1.02x
EV / Sales 2028 * 0.97x
Free-Float
85.55%
Yield 2027 *
2.75%
Yield 2028 * 3.44%
Sep. 21 Nipro Corporation(TSE:8086) dropped from FTSE All-World Index CI
Jul. 30 Nipro Corporation Receives Fda 510(K) Clearance for Elisio-Hx Dialyzer and Introduces Hds to the United States CI
Jul. 28 Vat Holding AG agreed to acquire 100% stake in Atonarp Inc. from Nipro Corporation for CHF 110 million. CI
Jul. 14 Jefferies Adjusts Nipro's Price Target to 1,700 Yen From 1,500 Yen, Keeps at Hold MT
May. 12 Nipro Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2026 and Fiscal Year Ending March 31, 2027 CI
May. 12 Nipro Corporation Announces Year-End Dividend for Fiscal Year Ended March 31, 2026, Payable on June 10, 2026; Provides Second Quarter-End and Year-End Dividend Guidance for Fiscal Year Ending March 31, 2027 CI
May. 01 Jefferies Adjusts Nipro's Price Target to 1,500 Yen From 1,300 Yen, Keeps at Hold MT
Mar. 11 Nipro Fixes Record Date for Fiscal 2026 Year-End Dividend MT
Feb. 08 Nipro Corporation Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
Dec. 24 Nipro Corporation Announces Establishment of Wholly Owned Subsidiary in Singapore CI
Nov. 10 Nipro Corporation Announces Dividend for the Second Quarter End of Fiscal Year Ending March 31, 2026, Payable on December 10, 2025 CI
25-06-10 Samsung Bioepis Partners With Nipro to Commercialize Biosimilars in Japan MT
25-06-09 Samsung Bioepis Co., Ltd. Enters into A Strategic Partnership with NIPRO Corporation for Commercialization of Multiple Biosimilars in Japan CI
1 day-3.22%
1 week-9.89%
Current month-4.49%
1 month-14.15%
3 months-16.54%
6 months-19.10%
Current year-11.51%
1 week 1,307
Extreme 1307
1,457.5
1 month 1,307
Extreme 1307
1,505
Current year 1,307
Extreme 1307
1,760.5
1 year 1,307
Extreme 1307
1,760.5
3 years 1,041
Extreme 1041
1,760.5
5 years 987
Extreme 987
1,760.5
10 years 908
Extreme 908
1,760.5
Manager TitleAgeSince
Director of Finance/CFO 58 2025-05-31
President 58 2025-05-31
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 81 2025-06-25
Director/Board Member 54 2009-05-31
Director/Board Member 58 2009-05-31
Change 5-day change 1-year change 3-year change Capi.($)
-3.22%-9.89%-12.34%+14.20% 1.38B
+0.84%-3.74%-26.69%+1.85% 169B
-0.07%-2.55%-9.53%+11.07% 110B
+0.90%+1.13%-24.83%+0.58% 106B
-1.24%-0.76%-49.04%-12.75% 73.87B
-0.24%+0.69%+0.16%+72.58% 58.98B
-0.86%+2.96%+13.57%+59.50% 51.28B
-0.71%-3.82%-7.72%-31.41% 48.16B
+0.12%-0.17%-18.21%+20.29% 40.84B
-1.01%-1.45%+28.48%-9.72% 32.21B
Average -0.55%-1.76%-10.62%+12.62% 69.16B
Weighted average by Cap. +0.02%-1.31%-16.36%+10.14%

Financials

2027 *2028 *
Net sales 701B 4.44B 3.95B 3.69B 3.36B 6.34B 427B 6.4B 44.61B 17.29B 218B 16.69B 16.33B 729B 4.62B 4.11B 3.83B 3.49B 6.59B 444B 6.65B 46.37B 17.97B 227B 17.35B 16.97B
Net income 15.39B 97.6M 86.72M 80.94M 73.77M 139M 9.38B 140M 979M 380M 4.8B 366M 358M 19.95B 127M 112M 105M 95.62M 180M 12.16B 182M 1.27B 492M 6.22B 475M 465M
Net Debt 501B 3.18B 2.82B 2.63B 2.4B 4.53B 305B 4.57B 31.87B 12.35B 156B 11.92B 11.67B 489B 3.1B 2.76B 2.57B 2.34B 4.42B 298B 4.46B 31.13B 12.06B 152B 11.65B 11.39B
Logo Nipro Corporation
Nipro Corp is a Japan-based company mainly engaged in the medical, pharmaceutical, and pharma packaging businesses. It has three segments. The Medical segment consists of the domestic business division and the international business division. The domestic business division sells medical devices related to injections and infusions, artificial organs, high-performance medicines, and dialysis. The international business division, centered on the head office, has medical device manufacturing and sales bases overseas for regional expansion, selling medical devices related to injections and infusions, artificial organs, and diabetes. The Pharmaceutical segment sells pharmaceuticals related to kit preparation containers on a contract basis from pharmaceutical companies. The Pharma Packaging segment sells medical glass products such as glass tubes and ampoules, thermos flasks, and kit preparation containers in Japan.
Employees
38,593
Date Price Change Volume
26-10-02 ¥1,307.00 -3.22% 1,223,500
26-10-01 ¥1,350.50 -1.32% 803,700
26-09-30 ¥1,368.50 -0.18% 1,015,200
26-09-29 ¥1,371.00 -4.46% 1,086,800
26-09-28 ¥1,435.00 -1.07% 849,400
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
1,307.00JPY
Average target price
1,996.00JPY
Spread / Average Target
+52.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 8086 Stock